DURHAM, N.C.--(BUSINESS WIRE)--Dec. 12, 2005--Aldagen, Inc. today announced that researchers from the Washington University School of Medicine presented results demonstrating that the unique human adult stem cell population isolated by Aldagen’s products (ALDHbr cells) are able to regenerate vascular function in a preclinical model of ischemic injury. The work, entitled “Bone marrow-derived aldehyde dehydrogenase expressing cells possess endothelial progenitor function in addition to hematopoietic repopulating ability, and aid in blood flow recovery after acute ischemic injury,” was presented at the 47th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.
